Syndax Pharmaceuticals: Strong Revuforj Momentum, Underappreciated Pipeline Catalysts Support Attractive Risk/Reward and Buy Rating

Analyst Jason Zemansky from Bank of America Securities maintained a Buy rating on Syndax Pharmaceuticals and keeping the price target at $27.00.

Jason Zemansky has given his Buy rating due to a combination of factors tied to Syndax’s recent operational and commercial performance. He points to stronger-than-expected preliminary fourth-quarter 2025 results for both Revuforj and Niktimvo, underscoring particularly robust quarter-over-quarter prescription growth for Revuforj following its label expansion into additional AML subsets. He views this momentum as evidence that Syndax’s commercial infrastructure is executing well and that its first-mover position in menin inhibition, coupled with strong patient access and support programs, provides a meaningful advantage as the market develops. Although Kura’s competing menin therapy may offer safety and dosing benefits, Zemansky believes the AML market is large and complex enough to support multiple successful agents, rather than resulting in a single winner.

Zemansky also highlights the company’s clinical pipeline as an important support for his positive stance. He notes the ongoing expansion of Revuforj into earlier-line and maintenance AML settings through pivotal trials starting in 2025, which could materially broaden the drug’s addressable market over time. In addition, he views the phase 2 MAXPIRe study of axatilimab in idiopathic pulmonary fibrosis as a significant 2026 catalyst that is not widely reflected in investor models, offering upside optionality if the data are favorable. Taken together—solid current revenue trends, strategic competitive positioning, and underappreciated pipeline catalysts—he concludes that Syndax’s risk/reward profile remains attractive and thus reiterates a Buy rating with a $27 price objective.

Zemansky covers the Healthcare sector, focusing on stocks such as Kura Oncology, Cytokinetics, and Syndax Pharmaceuticals. According to TipRanks, Zemansky has an average return of 20.0% and a 59.60% success rate on recommended stocks.

In another report released today, Barclays also maintained a Buy rating on the stock with a $35.00 price target.